Showing 1 - 2 results of 2 for search 'O'Hear, C', query time: 0.02s Refine Results
  1. 1
    MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results

    MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results by Sallman, D, Malki, MA, Asch, A, Wang, E, Jurcic, J, Bradley, T, Flinn, I, Pollyea, D, Kambhampati, S, Tanaka, T, Zeidner, J, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N

    Published 2022
    Conference item
  2. 2
    Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results

    Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results by Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, SN, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Gu, L, Tan, A, Chao, M, O'Hear, C, Lal, I, Vyas, P, Daver, N

    Published 2022
    Conference item

Search Tools: